ATE540935T1 - Chinazolinderivate - Google Patents
ChinazolinderivateInfo
- Publication number
- ATE540935T1 ATE540935T1 AT05789135T AT05789135T ATE540935T1 AT E540935 T1 ATE540935 T1 AT E540935T1 AT 05789135 T AT05789135 T AT 05789135T AT 05789135 T AT05789135 T AT 05789135T AT E540935 T1 ATE540935 T1 AT E540935T1
- Authority
- AT
- Austria
- Prior art keywords
- chinazoline derivatives
- chinazoline
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04292417 | 2004-10-12 | ||
PCT/GB2005/003846 WO2006040520A1 (en) | 2004-10-12 | 2005-10-07 | Quinazoline derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE540935T1 true ATE540935T1 (de) | 2012-01-15 |
Family
ID=35455960
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05789135T ATE540935T1 (de) | 2004-10-12 | 2005-10-07 | Chinazolinderivate |
Country Status (19)
Country | Link |
---|---|
US (1) | US8153643B2 (de) |
EP (1) | EP1802591B1 (de) |
JP (1) | JP4237242B2 (de) |
KR (1) | KR20070084172A (de) |
CN (1) | CN101072758B (de) |
AR (1) | AR051215A1 (de) |
AT (1) | ATE540935T1 (de) |
AU (1) | AU2005293336B2 (de) |
BR (1) | BRPI0516093A (de) |
CA (1) | CA2581516C (de) |
ES (1) | ES2378772T3 (de) |
HK (1) | HK1107339A1 (de) |
IL (1) | IL182094A0 (de) |
MX (1) | MX2007004403A (de) |
NO (1) | NO20071703L (de) |
NZ (1) | NZ554017A (de) |
TW (1) | TW200630347A (de) |
WO (1) | WO2006040520A1 (de) |
ZA (1) | ZA200702877B (de) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US20070123539A1 (en) * | 2005-10-20 | 2007-05-31 | University Of South Florida | Treatment of Restenosis and Stenosis with Dasatinib |
EP3208272B1 (de) | 2005-11-08 | 2020-01-08 | Vertex Pharmaceuticals Incorporated | Heterocyclische modulatoren von atp-bindenden kassettentransportern |
US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
WO2007113565A1 (en) * | 2006-04-06 | 2007-10-11 | Astrazeneca Ab | Naphthyridine derivatives as anti-cancer agents |
WO2008032764A1 (fr) | 2006-09-13 | 2008-03-20 | Kyowa Hakko Kirin Co., Ltd. | Dérivé hétérocyclique fusionné |
JP2010505962A (ja) * | 2006-10-09 | 2010-02-25 | 武田薬品工業株式会社 | キナーゼ阻害剤 |
JP2010505961A (ja) * | 2006-10-09 | 2010-02-25 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
CN101880280B (zh) | 2006-12-22 | 2014-07-16 | 中国科学院上海有机化学研究所 | 双环嘧啶酮以及其应用 |
EP2164840A2 (de) | 2007-05-09 | 2010-03-24 | Vertex Pharmaceuticals Incorporated | Modulatoren von cftr |
RS55559B1 (sr) | 2007-12-07 | 2017-05-31 | Vertex Pharma | Čvrste forme 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il) benzoeve kiseline |
EA201070700A1 (ru) | 2007-12-07 | 2011-06-30 | Вертекс Фармасьютикалз Инкорпорейтед | Способы получения циклоалкилкарбоксамидопиридинбензойных кислот |
FR2926554B1 (fr) | 2008-01-22 | 2010-03-12 | Sanofi Aventis | Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique |
JP5523352B2 (ja) | 2008-02-28 | 2014-06-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Cftr修飾因子としてのへテロアリール誘導体 |
GB0901834D0 (en) | 2009-02-04 | 2009-03-11 | Syngenta Ltd | Novel herbicides |
GB0901835D0 (en) | 2009-02-04 | 2009-03-11 | Syngenta Ltd | Novel herbicides |
JP2013505899A (ja) | 2009-09-28 | 2013-02-21 | チールー ファーマシューティカル カンパニー、リミテッド | チロシンキナーゼ阻害剤として有用な4−(置換アニリノ)キナゾリン誘導体 |
NZ602838A (en) | 2010-04-07 | 2015-06-26 | Vertex Pharma | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof |
CN102408426B (zh) * | 2011-09-14 | 2013-07-10 | 湖南有色凯铂生物药业有限公司 | 取代的芳香脲类化合物及其作为抗癌药物的应用 |
US20150225369A1 (en) * | 2012-08-29 | 2015-08-13 | Merck Patent Gmbh | Ddr2 inhibitors for the treatment of osteoarthritis |
JP6963896B2 (ja) | 2013-11-12 | 2021-11-10 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Cftr媒介性疾患の処置のための医薬組成物を調製する方法 |
RU2691136C2 (ru) | 2014-11-18 | 2019-06-11 | Вертекс Фармасьютикалз Инкорпорейтед | Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии |
JP7117323B2 (ja) * | 2017-04-27 | 2022-08-12 | アストラゼネカ・アクチエボラーグ | フェノキシキナゾリン化合物及び癌の処置におけるそれらの使用 |
KR102603153B1 (ko) | 2017-04-27 | 2023-11-15 | 아스트라제네카 아베 | C5-아닐리노퀴나졸린 화합물 및 암의 치료에서의 이의 용도 |
WO2019046668A1 (en) * | 2017-08-31 | 2019-03-07 | Kezar Life Sciences | AMIDE-SUBSTITUTED THIAZOLES AS INHIBITORS OF SECRETIC PROTEIN |
CN113061113A (zh) * | 2021-04-07 | 2021-07-02 | 中北大学 | 一种4-硝基咪唑的制备方法 |
CN115594602B (zh) * | 2021-07-09 | 2024-01-30 | 南京大学 | 一种可见光诱导的合成芳香胺的方法 |
WO2024112854A1 (en) * | 2022-11-22 | 2024-05-30 | Odyssey Therapeutics, Inc. | Inhibitors of ripk2 and medical uses thereof |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG64322A1 (en) | 1991-05-10 | 1999-04-27 | Rhone Poulenc Rorer Int | Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
TW321649B (de) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
GB9514265D0 (en) * | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
WO1997029079A1 (fr) | 1996-02-06 | 1997-08-14 | Japan Tobacco Inc. | Composes chimiques et utilisation pharmaceutique |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
EP0837063A1 (de) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazolinderivate |
JP2002506873A (ja) | 1998-03-18 | 2002-03-05 | アリアド・ファーマシューティカルズ・インコーポレイテッド | 複素環式シグナル伝達阻害剤、それを含む組成物 |
CN1158266C (zh) | 1998-10-01 | 2004-07-21 | 阿斯特拉曾尼卡有限公司 | 化合物 |
KR100860295B1 (ko) | 1998-10-08 | 2008-09-25 | 아스트라제네카 아베 | 퀴나졸린 유도체 |
ATE482946T1 (de) | 1999-02-10 | 2010-10-15 | Astrazeneca Ab | Chinazolinderivate als angiogenesehemmer und zwischenprodukte dafür |
EP1216228B1 (de) | 1999-09-17 | 2008-10-29 | Millennium Pharmaceuticals, Inc. | BENZAMIDE UND ÄHNLICHE INHIBITOREN VON FAKTOR Xa |
WO2001021596A1 (en) * | 1999-09-21 | 2001-03-29 | Astrazeneca Ab | Quinazoline derivatives and their use as pharmaceuticals |
GB9922173D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
GB9922171D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
PL354923A1 (en) * | 1999-09-21 | 2004-03-22 | Astrazeneca Ab | Quinazoline compounds and pharmaceutical compositions containing them |
US6531291B1 (en) | 1999-11-10 | 2003-03-11 | The Trustees Of Columbia University In The City Of New York | Antimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof |
EP1294709A2 (de) | 2000-01-28 | 2003-03-26 | AstraZeneca AB | Chinolinderivate und deren verwendung als aurora 2 kinase inhibitoren |
US6699997B2 (en) * | 2000-06-28 | 2004-03-02 | Teva Pharmaceutical Industries Ltd. | Carvedilol |
NZ522696A (en) * | 2000-06-28 | 2004-08-27 | Astrazeneca Ab | Substituted quinazoline derivatives and their use as inhibitors |
PL366001A1 (en) | 2000-09-01 | 2005-01-24 | Fmc Corporation | 1,4-disubstituted benzenes as insecticides |
EP1217000A1 (de) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Faktor Xa und Faktor VIIa Inhibitoren |
SE0101675D0 (sv) | 2001-05-11 | 2001-05-11 | Astrazeneca Ab | Novel composition |
AU2002363250A1 (en) | 2001-11-01 | 2003-05-12 | Icagen, Inc. | Pyrazole-amides and-sulfonamides |
GB0126433D0 (en) | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
ES2320980T3 (es) | 2001-11-03 | 2009-06-01 | Astrazeneca Ab | Derivados de quinazolina como agentes antitumorales. |
PL211694B1 (pl) | 2001-12-24 | 2012-06-29 | Astrazeneca Ab | Podstawiona pochodna chinazoliny, jej zastosowania oraz jej kompozycja farmaceutyczna |
EP1474420B1 (de) | 2002-02-01 | 2012-03-14 | AstraZeneca AB | Chinazoline verbindungen |
TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
AU2003252478A1 (en) | 2002-07-10 | 2004-02-02 | Ono Pharmaceutical Co., Ltd. | Ccr4 antagonist and medicinal use thereof |
EP1541564A1 (de) | 2002-09-10 | 2005-06-15 | Takeda Pharmaceutical Company Limited | F nfgliedrige heterocyclische verbindungen |
AU2003294142A1 (en) | 2002-12-24 | 2004-07-22 | Astrazeneca Ab | Therapeutic quinazoline derivatives |
WO2004058752A1 (en) | 2002-12-24 | 2004-07-15 | Astrazeneca Ab | Quinazoline compounds |
MY136174A (en) * | 2002-12-24 | 2008-08-29 | Astrazeneca Ab | Phosphonooxy quinazoline derivatives and their pharmaceutical use |
KR20060003351A (ko) | 2003-04-16 | 2006-01-10 | 아스트라제네카 아베 | 화합물 |
RU2342365C2 (ru) | 2003-05-01 | 2008-12-27 | Бристол-Маерс Сквибб Компани | Арилзамещенные пиразоламиды в качестве ингибиторов киназ |
EP1635837B1 (de) | 2003-06-02 | 2008-07-16 | AstraZeneca AB | (3-((chinazolin-4-yl)amino)-1h-pyrazol-1-yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs |
TW200505452A (en) * | 2003-06-17 | 2005-02-16 | Astrazeneca Ab | Chemical compounds |
GB0318422D0 (en) | 2003-08-06 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
DE602004017479D1 (de) | 2003-08-29 | 2008-12-11 | Pfizer | Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon |
US7732442B2 (en) | 2003-09-05 | 2010-06-08 | Ono Pharmaceutical Co., Ltd. | Chemokine receptor antagonist and medical use thereof |
CA2537812C (en) | 2003-09-26 | 2013-01-22 | Exelixis, Inc. | C-met modulators and method of use |
WO2006040522A1 (en) | 2004-10-12 | 2006-04-20 | Astrazeneca Ab | Quinoline derivatives |
US20090036474A1 (en) | 2004-10-12 | 2009-02-05 | Patrick Ple | Quinazoline derivatives for use against cancer |
AU2006204724A1 (en) | 2005-01-14 | 2006-07-20 | Millennium Pharmaceuticals, Inc. | Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity |
GB0509224D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of intracellular enzymatic activity |
GB0509227D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
EP1994023A1 (de) | 2006-03-02 | 2008-11-26 | AstraZeneca AB | Chinazolinderivate |
US20090042910A1 (en) | 2006-03-02 | 2009-02-12 | Frederic Henri Jung | Quinoline derivatives for treating cancer |
JP2009528336A (ja) | 2006-03-02 | 2009-08-06 | アストラゼネカ アクチボラグ | キノリン誘導体 |
WO2007113565A1 (en) | 2006-04-06 | 2007-10-11 | Astrazeneca Ab | Naphthyridine derivatives as anti-cancer agents |
WO2007113548A1 (en) | 2006-04-06 | 2007-10-11 | Astrazeneca Ab | Naphthyridine derivatives |
-
2005
- 2005-10-07 MX MX2007004403A patent/MX2007004403A/es active IP Right Grant
- 2005-10-07 EP EP05789135A patent/EP1802591B1/de active Active
- 2005-10-07 ES ES05789135T patent/ES2378772T3/es active Active
- 2005-10-07 US US11/665,125 patent/US8153643B2/en not_active Expired - Fee Related
- 2005-10-07 KR KR1020077010679A patent/KR20070084172A/ko not_active Application Discontinuation
- 2005-10-07 JP JP2007536244A patent/JP4237242B2/ja not_active Expired - Fee Related
- 2005-10-07 AU AU2005293336A patent/AU2005293336B2/en not_active Ceased
- 2005-10-07 NZ NZ554017A patent/NZ554017A/en not_active IP Right Cessation
- 2005-10-07 BR BRPI0516093-6A patent/BRPI0516093A/pt active Search and Examination
- 2005-10-07 CN CN2005800420488A patent/CN101072758B/zh not_active Expired - Fee Related
- 2005-10-07 WO PCT/GB2005/003846 patent/WO2006040520A1/en active Application Filing
- 2005-10-07 CA CA2581516A patent/CA2581516C/en not_active Expired - Fee Related
- 2005-10-07 AT AT05789135T patent/ATE540935T1/de active
- 2005-10-12 AR ARP050104277A patent/AR051215A1/es not_active Application Discontinuation
- 2005-10-12 TW TW094135541A patent/TW200630347A/zh unknown
-
2007
- 2007-03-21 IL IL182094A patent/IL182094A0/en unknown
- 2007-03-30 NO NO20071703A patent/NO20071703L/no not_active Application Discontinuation
- 2007-04-05 ZA ZA200702877A patent/ZA200702877B/xx unknown
- 2007-11-21 HK HK07112721.4A patent/HK1107339A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2005293336B2 (en) | 2009-05-28 |
IL182094A0 (en) | 2007-07-24 |
CN101072758B (zh) | 2013-07-31 |
US20090233924A1 (en) | 2009-09-17 |
KR20070084172A (ko) | 2007-08-24 |
MX2007004403A (es) | 2007-04-27 |
JP2008515959A (ja) | 2008-05-15 |
EP1802591A1 (de) | 2007-07-04 |
HK1107339A1 (en) | 2008-04-03 |
JP4237242B2 (ja) | 2009-03-11 |
ZA200702877B (en) | 2008-09-25 |
WO2006040520A1 (en) | 2006-04-20 |
BRPI0516093A (pt) | 2008-08-19 |
AU2005293336A1 (en) | 2006-04-20 |
US8153643B2 (en) | 2012-04-10 |
CA2581516C (en) | 2013-06-11 |
AR051215A1 (es) | 2006-12-27 |
NO20071703L (no) | 2007-07-04 |
EP1802591B1 (de) | 2012-01-11 |
TW200630347A (en) | 2006-09-01 |
NZ554017A (en) | 2010-06-25 |
CN101072758A (zh) | 2007-11-14 |
ES2378772T3 (es) | 2012-04-17 |
CA2581516A1 (en) | 2006-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY2019034I1 (el) | 4-φαινυλαμινο-κιναζολιν-6-υλ-αμιδια | |
IS8578A (is) | 3- karbamoýl - 2- pýridón afleiður | |
ATE394399T1 (de) | Tetrahydropyridoindolderivate | |
DK1761541T3 (da) | Pyrrazolo-pyrimidin-derivater | |
ATE540935T1 (de) | Chinazolinderivate | |
ATE417830T1 (de) | Sulfonylbenzimidazolderivate | |
ATE553079T1 (de) | Heteroarylphenylharnstoffderivat | |
ATE392425T1 (de) | Thiazolyl-dihydro-indazole | |
ATE520680T1 (de) | Hiv-hemmende 5-heterocyclylpyrimidine | |
ATE459633T1 (de) | Makrolide | |
DE602006010581D1 (de) | 4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate | |
ATE485294T1 (de) | Azaindol-2-carboxamid-derivate | |
ATE430142T1 (de) | Phenylpiperazin-methanon-derivate | |
ATE527255T1 (de) | Aryl-isoxazol-4-yl-imidazol-derivate | |
DK1971588T3 (da) | Tiglien-3-onderivater | |
ATE404542T1 (de) | 4-phenylpyrimidin-2-carbonitrilderivate | |
DK1740574T3 (da) | 4-amino-5-cyanopyrimidinderivater | |
AT500198B8 (de) | Ladewagen | |
ATE389633T1 (de) | Omega-phenyloctanamide | |
ATE541837T1 (de) | Oxaphenanthren-derivate | |
DE502005007686D1 (de) | Gutverteileinrichtung | |
AT500249A3 (de) | Scheibenegge | |
DE602006019209D1 (de) | Fluoroalkylpyrrolidin-derivate | |
DE602005010520D1 (de) | Plamabildschirm | |
AT7802U3 (de) | Parfum-zerstäuber |